Cellbion Co

Cellbion Co Assets per Share

The Total Assets per Share of Cellbion Co (308430.KQ) as of Oct 30, 2026 is 3,467.01 KRW. In the previous year, Total Assets per Share was 3,389.51 KRW — a change of 2.29% (higher).

Assets per Share

3,467.01KRW

YoY

2.29%

Last updated:

Total Assets per Share of Cellbion Co is 2025 3,467.01 KRW. Total Assets per Share of Cellbion Co was 2024 3,389.51 KRW. It decreases by 2.29% higher compared to the previous year.

The Cellbion Co Assets per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Assets per Share
Date
Assets per Share
Jan 1, 2021
1,364.43 KRW
Jan 1, 2022
988.73 KRW
Jan 1, 2023
1,117.65 KRW
Jan 1, 2024
3,389.51 KRW
Jan 1, 2025
3,467.01 KRW
The Cellbion Co Assets per Share history
YEARAssets per ShareYoY
3,467.01KRW+2.29%
3,389.51KRW+203.27%
1,117.65KRW+13.04%
988.73KRW-27.54%
1,364.43KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cellbion Co Stock analysis

What does Cellbion Co do? Cellbion Co Ltd generates revenue through the manufacture and sale of pharmaceuticals, including innovative diagnostic and therapeutic new drugs developed by the company. The firm also sells generic prescription drugs and provides contract development and manufacturing organization (CDMO) services for clinical trial drugs. Additionally, the company produces cosmetic products under its own brand. The primary customers are healthcare providers, hospitals, and pharmaceutical companies seeking drug development and manufacturing solutions. The company's product segments include pharmaceuticals, generic prescription drugs, CDMO services, and cosmetics. Key buyers are healthcare institutions, pharmaceutical firms, and consumers purchasing cosmetics. Cellbion Co Ltd targets the Korean market with its domestic operations, focusing on both B2B and B2C segments through its diverse product portfolio. Cellbion Co Ltd's revenue streams are derived from the sale of pharmaceuticals, generic drugs, CDMO services, and cosmetic products. The company's business model emphasizes innovation in drug development alongside traditional pharmaceutical manufacturing, with a focus on serving the domestic Korean healthcare sector and expanding its CDMO capabilities for global clinical trials. Cellbion Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cellbion Co stock

Total Assets per Share of Cellbion Co is 3,467.01 KRW in 2025.

Total Assets per Share of Cellbion Co changed from 3,389.51 KRW to 3,467.01 KRW, representing a 2.29% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets per Share Cellbion Co since 2006 – with annual values, charts, and detailed analysis.

Assets per share divides total assets by shares outstanding, indicating the total resource base backing each share of stock.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Cellbion Co

All Key Metrics — Cellbion Co